U.S. Pharma Tariffs And MFN Become Law After April 2 Update

By Mathini Ilancheran, senior delivery lead - research, R&D, Beroe Inc.

On April 2, 2026, President Trump signed a sweeping executive order converting over a year of tariff threats into binding trade law. Issued under Section 232 of the Trade Expansion Act of 1962, the proclamation imposes a 100% ad valorem tariff on patented pharmaceutical products and their active pharmaceutical ingredients (APIs), effective July 31, 2026 for large companies and September 29, 2026 for smaller manufacturers.^1,2 Generic pharmaceuticals, biosimilars, and certain specialty products, including orphan drugs, remain exempt for now, with a formal review of generics mandated within one year.²

This is not a price shock. It is a structural reset. For sponsors, CROs, CDMOs, and central labs, the clock is running.

The Policy Architecture

The proclamation establishes a tiered tariff framework. The rates are determined by country of origin, whether the importing company has a Commerce-approved onshoring plan, and whether it has a signed MFN pricing agreement with HHS. ^[2]

Source: White House Presidential Proclamation, April 2, 2026, clauses 3(a)–3(e) and clause 11.² Note: The proclamation does not explicitly name China, India, or Singapore — these countries fall under the default 100% rate by not being listed in any preferential tier.

Three structural features distinguish this order from the October 2025 tariff framework.¹⁰

1. Tariff exposure is now primarily a function of company-level MFN deal status, not geography alone; a fully executed agreement confers a 0% rate regardless of manufacturing origin.²
2. The 20% onshoring rate is transitional, not stable; it escalates automatically to 100% on April 2, 2030.²
3. The White House reports that Section 232 pressure has already triggered approximately $400 billion in new domestic pharma investment commitments, which will rapidly compete with the U.S. manufacturing capacity that sponsors are simultaneously trying to reserve.¹

Impact Across The Drug Development Value Chain

The value chain exposure mapped in the October 2025 framework ¹⁰ remains directionally valid. The April 2 order introduces additional nuance at each stage, particularly where MFN deal status now intersects with country of origin risk.

Derived from White House Proclamation²; ITIF analysis⁷; updated from prior framework^10,11

Strategic Procurement Priorities

Five priorities require immediate action, building on the eight-point framework in the October 2025 analysis.¹⁰

Conclusion

The April 2, 2026 executive order converts 12 months of Section 232 tariff pressure into enforceable trade law. The default 100% rate applies to all countries not explicitly listed in the proclamation's preferential tiers, and the proclamation names only the EU, Japan, South Korea, Switzerland/Liechtenstein, and the U.K. All other manufacturing origins fall under the default rate unless a company-level MFN or onshoring deal applies.²

For sponsors, CROs, CDMOs, and the full outsourced network, the immediately actionable priorities are:

• Map MFN deal status across all supplier relationships at the product level.
• Re-cost trial budgets against the July 31 and September 29 effective dates, and reserve U.S. fill/finish capacity before $400 billion in onshoring commitments compete for the same slots. ^1,2

The organizations that treat these deadlines as operational triggers and not compliance exercises will turn tariff volatility into a sourcing and capacity advantage.

References:

1. White House, "Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products," April 2, 2026. Available: https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/
2. White House, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States," Presidential Proclamation, April 2, 2026. Available: https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/
3. CNBC, "Trump administration sets up to 100% tariffs on some imported drugs, with many companies exempt," April 2, 2026. Available: https://www.cnbc.com/2026/04/02/trump-pharmaceutical-tariffs-100percent.html
4. Axios, "Trump hits drugmakers with tariffs on some pharmaceutical drugs," April 2, 2026. Available: https://www.axios.com/2026/04/02/trump-drug-prices-tariffs
5. The Hill, "Trump signs order imposing 100 percent tariff on brand name drugs," April 2, 2026. Available: https://thehill.com/policy/healthcare/5813970-trump-signs-drug-tariffs/
6. Pharmaceutical Executive, "President Trump Imposes 100% Tariffs on Branded Pharmaceuticals," April 3, 2026. Available: https://www.pharmexec.com/view/president-trump-imposes-100-tariffs-branded
7. ITIF, "Trump Pharma Tariffs: Wrong Rx for U.S. Patients, Manufacturing, and Innovation," April 3, 2026. Available: https://itif.org/publications/2026/04/03/trump-pharma-tariffs-wrong-rx-for-us-patients-manufacturing-and-innovation/
8. BIO, "BIO Statement on the Section 232 Pharmaceutical Proclamation," April 2026. Available: https://www.bio.org/press-release/bio-statement-section-232-pharmaceutical-proclamation
9. PharmaSource, "What to Expect in Pharma Manufacturing in 2026," January 2026. Available: https://pharmasource.global/content/expert-insight/what-to-expect-in-pharma-manufacturing-in-2026-industry-leaders-share-their-predictions/
10. M. Ilancheran, "100% U.S. Drug Tariffs: Implications for Pharma and Outsourcing," Clinical Leader / Beroe Inc., Oct. 17, 2025. Available: https://www.clinicalleader.com/doc/u-s-drug-tariffs-implications-for-pharma-and-outsourcing-0001
11. M. Ilancheran, "U.S. Pharma Tariffs and MFN in 2026: Manufacturing and Procurement Impact," Clinical Leader / Beroe Inc., Feb. 18, 2026. Available: https://www.clinicalleader.com/doc/u-s-pharma-tariffs-and-mfn-in-manufacturing-and-procurement-impact-0001

About The Author:

Mathini Ilancheran is a Research Manager and an expert in market intelligence and industry analysis, specializing in delivering strategic insights that help Fortune 500 companies make informed decisions. With a focus on global pharma, biotech, and medical devices, she brings deep expertise in value chain analysis, industry and technology trends, competitive intelligence, and strategy. Mathini has authored 45+ publications on R&D outsourcing, offering actionable perspectives that guide global enterprises in optimizing outsourcing practices, category management, and long-term planning.